US 12,246,017 B2
Replication stress pathway agent compositions and methods for treating cancer
Christian Hassig, San Diego, CA (US); Ryan Hansen, San Diego, CA (US); Snezana Milutinovic, San Diego, CA (US); Jason Christiansen, Carlsbad, CA (US); Zachary D. Hornby, San Diego, CA (US); Sudhir Chowdhry, San Diego, CA (US); Anthony Celeste, San Diego, CA (US); Kristen Turner, San Diego, CA (US); and Deepti Wilkinson, San Diego, CA (US)
Assigned to BOUNDLESS BIO, INC., San Diego, CA (US)
Filed by Boundless Bio, Inc., San Diego, CA (US)
Filed on Mar. 24, 2023, as Appl. No. 18/189,453.
Application 18/189,453 is a continuation of application No. 18/048,573, filed on Oct. 21, 2022, granted, now 11,642,345.
Application 18/048,573 is a continuation of application No. 17/568,434, filed on Jan. 4, 2022, granted, now 11,547,711, issued on Jan. 10, 2023.
Application 17/568,434 is a continuation of application No. PCT/US2021/045556, filed on Aug. 11, 2021.
Claims priority of provisional application 63/168,120, filed on Mar. 30, 2021.
Claims priority of provisional application 63/064,555, filed on Aug. 12, 2020.
Prior Publication US 2023/0248728 A1, Aug. 10, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/517 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/517 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 20 Claims
 
1. A method of treating an ecDNA-associated cancer in a subject comprising:
administering to the subject a therapeutically effective amount of (i) a replication stress pathway agent (RSPA), and (ii) a cancer-targeted therapeutic agent,
wherein cells of the ecDNA-associated cancer have an ecDNA signature, wherein the cells of the ecDNA-associated cancer comprise an amplification of a KRAS gene or portion thereof and the amplification is present on ecDNA, and
wherein the cancer-targeted therapeutic agent is directed against a KRAS protein encoded by the KRAS gene,
thereby decreasing growth or number of cells of the ecDNA-associated cancer in the subject.